Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Vaccines for protecting against influenza
H2283 Vaccines for protecting against influenza
Patent Drawings:

Inventor: Stohr, et al.
Date Issued: September 3, 2013
Application:
Filed:
Inventors:
Assignee:
Primary Examiner: Pihulic; Daniel
Assistant Examiner:
Attorney Or Agent: Morrison & Foerster LLP
U.S. Class: 424/209.1; 424/206.1
Field Of Search: 424/209.1; 424/206.1
International Class: A61K 39/145; A61P 31/16; C12N 7/00; A61K 39/295
U.S Patent Documents:
Foreign Patent Documents: 0870508; 1260581; 2859633; WO-92/15582; WO-95/18861; WO-96/37624; WO-97/37000; WO-97/37001; WO-98/46262; WO-99/64068; WO-00/60050; WO-01/04333; WO-01/21151; WO-01/22972; WO-01/22992; WO-01/64846; WO-01/83794; WO-01/85938; WO-02/18383; WO-02/28422; WO-02/067983; WO-02/074336; WO-02/097072; WO-03/011223; WO-03/023021; WO-03/023025; WO-03/043415; WO-03/076601; WO-03/082272; WO-03/105769; WO-2004/018455; WO-2004/060308; WO-2004/064715; WO-2004/064759; WO-2004/087153; WO-2005/042728; WO-2005/102049; WO-2005/113756; WO-2005/113758; WO-2006/027698; WO-2006/067211; WO-2006/071563; WO-2006/108846; WO-2007/002008; WO-2007/052163
Other References: Andrianov et al. (1998) Biomaterials 19:109-115. cited by applicant.
Banzhoff (2000) Immunology Letters 71:91-96. cited by applicant.
Beignon et al. (2002) Infect Immun 70:3012-3019. cited by applicant.
Brands et al. (1999) Dev Biol Stand 98:93-100. cited by applicant.
Briggs (1991) J Parenter Sci Technol. 45:7-12. cited by applicant.
Bright et al. (2008) PLoS ONE 3:e1501. cited by applicant.
Bruhl et al. (2000) Vaccine 19:1149-58. cited by applicant.
Caillet et al. (2010) Vaccine 28:3076-3079. cited by applicant.
Centers for Diseases Control and Prevention. (May 22, 2009) MMWR 58(19):521-56. cited by applicant.
Chen et al. (2003) Vaccine 21:2830-2836. cited by applicant.
Clark et al. (2009) NEJM 361:2424-35. cited by applicant.
Cooper (1995) Pharm Biotechnol 6:559-80. cited by applicant.
Couceiro & Baum (1994) Mem Inst Oswaldo Cruz 89(4):587-91. cited by applicant.
Crevar & Ross (2008) Virology Journal 5(131), 9 pages. cited by applicant.
de Jong et al. (2003) Dev. Biol (Basel) 115:63-73. cited by applicant.
De Libero et al. (2005) Nature Reviews Immunology 5:485-496. cited by applicant.
Del Giudice et al. (2009) Sci Transl Med. 1(12):1-3. cited by applicant.
Dolin et al. (1977) J Infect. Dis. 136(Suppl.):S435-S442. cited by applicant.
Doroshenko & Halperin (2009) Expert Rev Vaccines 8:679-88. cited by applicant.
Dyakonova et al. (2004) Int Immunopharmacol 4(13):1615-23. cited by applicant.
Efferson et at. (2006) J Viral. 80(1):383-94. cited by applicant.
Ershler et al. (2007) Ann N Y Acad Sci. 1112:375-84. cited by applicant.
Evans et al. (2003) Expert Rev Vaccines 2:219-229. cited by applicant.
Galli et al. (2009) PNAS USA 106:7962-7. cited by applicant.
Gambaryan & Matrosovich (1992) J Virol Methods 39(1-2):111-23. cited by applicant.
Garten et al. (2009) Science 325:197-201. cited by applicant.
GenBank sequence GI:325176, (Aug. 2, 1993), 1 page. cited by applicant.
GenBank sequence GI:325237, (Aug. 2, 1993), 1 page. cited by applicant.
Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th edition, ISBN: 0683306472. cited by applicant.
Goff et al (2004) J Am. Chem. Soc. 126:13602-13603. cited by applicant.
Greenbaum et at. (2004) Vaccine 22:2566-2577. cited by applicant.
Greenberg et al. (2009) NEJM 361(25):2405-2413. cited by applicant.
Guidance for Industry: Bioanalytical Method Validation, (May 2001). U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM). cited by applicant.
Halperin et al. (2002) Vaccine 20:1240-7. cited by applicant.
Halperin et al. (1979) Am J Public Health 69:1247-1250. cited by applicant.
Hehme et al. (2004) Virus Res. 103(1-2):163-171. cited by applicant.
Herbert et al. (1979) J Infect Dis 140:234-238. cited by applicant.
Herlocher et al. (2004) J Infect Dis 190(9):1627-30. cited by applicant.
Hoffmann et al. (2002) Vaccine 20:3165-3170. cited by applicant.
Hoffmann et al. (2000) Virology 267(2):310-7. cited by applicant.
Huckriede et al. (2003) Methods Enzymol 373:74-91. cited by applicant.
Hussain et al. (2010) Vaccine 28(22):3848-3855. cited by applicant.
Ji et al. (2002) Biotechniques 32:1162-7. cited by applicant.
Jin et al. (2003) Virology 306:18-24. cited by applicant.
Johnson et al. (1999) Bioorg Med Chem Lett 9:2273-2278. cited by applicant.
Jones (2003) Curr Opin Invest Drugs 4:214-218. cited by applicant.
Keitel et al. (1996) Clin Diagn Lab Immunol 3:507-10. cited by applicant.
Kistner et al. (1998) Vaccine 16:960-8. cited by applicant.
Kistner et al. (1999) Dev Biol Stand 98:101-10. cited by applicant.
Kistner et al. (2010) PLoS ONE 5(2): e9349. cited by applicant.
Kitikoon et al. (2010) Vaccine 28:523-31. cited by applicant.
Lahijani et al. (1998) Hum Gene Ther. 9:1173-80. cited by applicant.
Liu et al. (2003) Virology 314:580-90. cited by applicant.
Lokteff et al. (2001) Biologicals 29:123-32. cited by applicant.
Lundblad (2001) Biotechnology and Applied Biochemistry 34:195-7. cited by applicant.
Mann et al. (2004) Vaccine 2:2425-9. cited by applicant.
Mastrosovich et al. (1999) J Virol 73:1146-55. cited by applicant.
McCullers et al. (1999) J Virol 73:7343-8. cited by applicant.
Meraldi et al. (2003) Vaccine 21:2485-2491. cited by applicant.
Munster et al. (2009) Science 325:481-3. cited by applicant.
Neumann et al. (2005) Proc Natl Acad Sci USA 102:16825-29. cited by applicant.
Nony et al. (2001) Vaccine 27:3645-51. cited by applicant.
Oki et al. (2004) J Clin. Investig. 113:1631-1640. cited by applicant.
Ozaki et al. (2004) J. Virol. 78:1851-7. cited by applicant.
Pajak et al. (2003) Vaccine 21:836-842. cited by applicant.
Partidos et al. (1999) Immunol Lett 67:209-216. cited by applicant.
Pau et al. (2001) Vaccine 19:2716-21. cited by applicant.
Payne et al. (1998) Adv Drug Delivery Review 31:185-196. cited by applicant.
Peppoloni et al. (2003) Expert Rev Vaccines 2:285-293. cited by applicant.
Piascik (2003) J Am Pharm Assoc (Wash DC). 43:728-30. cited by applicant.
Pine et al. (2002) J Control Release 85:263-270. cited by applicant.
Pizza et al. (2000) Int J Med Microbiol 290:455-461. cited by applicant.
Pizza et al. (2001) Vaccine 19:2534-2541. cited by applicant.
Poole & Mussett (1989) J Biol Stand 17:161-71. cited by applicant.
Poole et al. (1997) J Endotoxin Res 4:221-31. cited by applicant.
Potter & Oxford (1979) Br Med Bull 35:69-75. cited by applicant.
Quan et al. (2010) PloS ONE 5(2): e9161. cited by applicant.
Roman et al. (2010) Vaccine 28:1740-45. cited by applicant.
Ryan et al. (1999) Infect Immun 67:6270-6280. cited by applicant.
Scharton-Kersten et al. (2000) Infect Immun 68:5306-5313. cited by applicant.
Schellack et al. (2006) Vaccine 24:5461-72. cited by applicant.
Signorelli & Hadden (2003) Int Immunopharmacol 3(8):1177-86. cited by applicant.
Smith et al. (2009) Nature 459:1122-5. cited by applicant.
Stanley (2002) Clin Exp Dermatol 27:571-577. cited by applicant.
Stephenson et al. (2003) Vaccine 21:16887-93. cited by applicant.
Stevens et al. (2006) J Mol Biol 355:1143-55. cited by applicant.
Subbarao et al. (2003) Virology 305:192-200. cited by applicant.
Talbot et al. (2008) Vaccine 26:4057-61. cited by applicant.
Tebbey et al. (2000) Vaccine 18:2723-34. cited by applicant.
Treanor et al. (1996) J Infect Dis 173:1467-70. cited by applicant.
Tree et al. (2001) Vaccine 19:3444-50. cited by applicant.
Powell & Newman, eds., (1995). Vaccine Design: The Subunit and Adjuvant Approach Plenum Press (ISBN 0-306-44867-X). cited by applicant.
Plotkin & Orenstein, eds., (2004). Vaccines. 4th edition, ISBN: 0-7216-9688-0. cited by applicant.
Vajo et al. (2010) Lancet 375:49-55. cited by applicant.
Vasilakos et al. (2000) Cell Immunol. 204(1):64-74. cited by applicant.
Webby et al. (2004) Lancet 363:1099-103. cited by applicant.
Wong et al. (2003) J Clin Pharmacol 43(7):735-42. cited by applicant.
Wu et al. (2004) Antiviral Res. 64(2):79-83. cited by applicant.
Yang et al. (2004) Anew. Chem. Int. Ed. 43:3818-3822. cited by applicant.
Zangwill et al. (2008) J Infect Dis. 197(4):580-3. cited by applicant.
Zurbriggen et al. (2003) Expert Rev Vaccines 2:295-304. cited by applicant.









Abstract: A vaccine containing a H1 subtype influenza A virus hemagglutinin is either unadjuvanted or is adjuvanted but not with an oil-in-water emulsion adjuvant. The vaccine is suitable for immunizing a patient against swine flu. The vaccine may be monovalent. The vaccine may include two different H1 subtype influenza A virus hemagglutinins, wherein (i) the first H1 subtype influenza A virus hemagglutinin is more closely related to SEQ ID NO: 1 than to SEQ ID NO: 3 and (ii) the second H1 subtype influenza A virus hemagglutinin is more closely related to SEQ ID NO: 3 than to SEQ ID NO: 1. A monovalent vaccine may be administered in conjunction with a trivalent A/H1N1-A/H3N2 B seasonal influenza vaccine. Other embodiments are also disclosed, such as reassortant viruses.
Claim: The invention claimed is:

1. A method for immunizing a subject, comprising administering two separate doses of unadjuvanted monovalent influenza vaccine to the subject, wherein (a) the twodoses are administered from 1-6 weeks apart, and (b) each monovalent vaccine contains a H1 subtype influenza A virus hemagglutinin which is more closely related to SEQ ID NO: 1 than to SEQ ID NO: 3.

2. A method for immunizing a subject, comprising administering two separate doses of unadjuvanted monovalent influenza vaccine to the subject, wherein (a) the two doses are administered from 1-6 weeks apart, and (b) each monovalent vaccinecontains a H1 subtype influenza A virus hemagglutinin which has at least 85% sequence identity to SEQ ID NO: 1.

3. A method for immunizing a subject, comprising administering to them by an intradermal route an unadjuvanted immunogenic composition comprising a H1 subtype influenza A virus hemagglutinin which is more closely related to SEQ ID NO: 1 than toSEQ ID NO: 3.

4. A method for immunizing a subject, comprising administering to them by an intradermal route an unadjuvanted immunogenic composition comprising a H1 subtype influenza A virus hemagglutinin which has at least 85% sequence identity to SEQ IDNO: 1.
Description:
 
 
  Recently Added Patents
Touch sensing technology
Wheel
Quinoline compounds and their use for treating viral infection
Composite high reflectivity layer
Film, polarizing plate and display device, and method of manufacturing film
Composite aircraft floor system
Regenerative power storage system mounted on DC electric railway car
  Randomly Featured Patents
Tundish with weirs
Method of setting an inaudible alert mode in a radio pager
Plate bending machine equipped with a plate clamping manipulator and a plate position detecting device
Method of and apparatus for aerobic decomposition of organic solids
Chirped pulse fiber amplifier
Herbicidally active pyridine sulfonyl urea derivatives
Pressure-sensitive adhesive sheet material
Pacing in the presence of electromagnetic interference
Nucleic acids encoding pancreatic islet cell antigens obtained by molecular cloning
Liquid crystal display panel